世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

スマートピル市場：用途別（カプセル内視鏡、ドラッグデリバリー、患者モニタリング）、対象部位別（食道、小腸、大腸、胃）、エンドユーザー別（病院、診断センター）、地域別 - 2028年までの世界予測


Smart Pills Market by Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring), Target Area (Esophagus, Small Intestine, Large Intestine, Stomach), End User (Hospitals, Diagnostic Centers), Region - Global Forecast to 2028

世界のスマートピル市場は、2023年の6億米ドルから2028年には11億米ドルに達し、予測期間中のCAGRは11.8％と予測されている。この市場の成長の主な原動力は、非侵襲的診断モニタリング装置に対する需要の高まり、... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年6月23日 US$4,950
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		150 137 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界のスマートピル市場は、2023年の6億米ドルから2028年には11億米ドルに達し、予測期間中のCAGRは11.8％と予測されている。この市場の成長の主な原動力は、非侵襲的診断モニタリング装置に対する需要の高まり、カプセル内視鏡の技術進歩、カプセル内視鏡技術の著しい進歩である。高度なドラッグデリバリーシステムに対する需要の高まりと迅速な医薬品開発プロセスの必要性は、予測期間中に市場プレーヤーに機会を提供すると予想される。一方、一部の条件下ではスマートピルの技術的非力さが、今後数年間は市場の成長をある程度抑制すると予想される


"バイタルサインモニタリング分野は予測期間中最も高いCAGRで成長すると予測される"
アプリケーションに基づき、スマートピル市場は標的薬開発、カプセル内視鏡、バイタルサインモニタリングの各セグメントに分けられる。バイタルサインモニタリングセグメントは予測期間中に最も高いCAGRで成長すると予測されている。これは、体温の正確で精密な測定の必要性が高まっていること、従来のバイタルサインモニタリング機器ではデジタルヘルスシステムとの統合が不十分であることによる。医療システムが相互運用性と包括的な患者記録を目指しているため、デジタルヘルスシステムとスムーズに統合するバイタルサインモニタリングデバイスの必要性が高まっている。合理的な統合に対する需要の高まりは、高度な接続性とデジタルヘルスシステムとの互換性により、スマートピルの採用を増加させると予想される。

"予測期間中、大腸ターゲット領域が市場シェア第2位を占めた。"
スマートピル市場は、ターゲット領域に基づいて、小腸、大腸、食道、胃に大別される。大腸のターゲット領域は2022年に2番目に大きなシェアを占め、これは大腸癌の症例が増加していること、炎症性腸疾患やその他の消化器疾患の効果的なスクリーニング、診断、モニタリングの必要性に起因している。大腸癌の症例増加は、スマートピルが従来の方法では可視化が困難な大腸の領域に到達できることから、大腸におけるスマートピルの採用拡大に寄与している。


診断センターセグメントが2022年の市場で第2位のシェアを占める
エンドユーザーに基づくと、スマートピル市場は診断センター、病院、その他のエンドユーザーに大別される。診断センターは、スマートピル市場で2番目に大きなエンドユーザーである。これは、技術の進歩、非侵襲的診断の需要、診断精度の向上に起因している。診断センターにおけるスマートピルの統合は、診断能力の拡大、患者体験の向上、業務効率の改善、遠隔診断の促進能力を提供することにより、利用を促進する重要な要因となっている。



2022年、欧州がスマートピル市場で第2位のシェアを占める
2022年、欧州はスマートピル市場で第2位のシェアを占めた。これは、高齢化人口の増加や消化管出血に対するカプセル内視鏡の利用増加などの要因によるものである。欧州消化器内視鏡学会（ESGE）のガイドラインによるカプセル内視鏡検査の推奨は、医療従事者に標準化されたアプローチを提供し、患者に提供されるケアの質を高める。その結果、消化管出血に対するカプセル内視鏡検査の利用増加により、スマートピルや関連技術の需要が高まっている。


スマートピル市場の主要参入企業のプロファイルの内訳：
- 企業タイプ別：ティア1- 60%、ティア2- 30%、ティア3-10
- 役職別Cレベル幹部：50％、取締役：40％、その他：10
- 地域別北米45%、欧州35%、アジア太平洋地域15%、その他地域5%。


スマートピル市場の主要企業
スマートピルズの主要企業には、株式会社アールエフ（日本）、etectrx（米国）、オリンパス株式会社（日本）、BodyCap（フランス）、重慶金山科技（集団）有限公司（中国）、Check-Cap Ltd. （イスラエル）、CapsoVision,Inc.(Ltd.（イスラエル）、CapsoVision,Inc.（米国）、ANX Robotica Corp.（米国）、Medtronic plc（米国）、IntroMedic（韓国）、Shenzen Jifu Medical Technology Co.Ltd.（中国）、Otsuka America Pharmaceutical, Inc.）
調査範囲
当レポートでは、スマートピル市場を分析し、用途、対象地域、エンドユーザーなど様々なセグメントに基づいて、市場規模や今後の成長可能性を推計することを目的としています。また、市場で入手可能な様々なスマートピル製品の製品ポートフォリオマトリックスも掲載しています。また、同市場における主要企業の競争分析も行っており、企業プロフィール、サービス内容、主要市場戦略などを掲載しています。

レポート購入の理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業にとっても、市場の動向を把握する上で有益であり、ひいては市場シェアを拡大する上で役立ちます。本レポートを購入される企業は、以下の戦略のいずれか、または任意の組み合わせを使用して、市場での地位を強化することができます。

本レポートは、以下のポイントに関する洞察を提供する：
- 市場への浸透：世界のスマートピル市場のトップ企業が提供する製品ポートフォリオに関する包括的な情報。当レポートでは、この市場を用途別、対象地域別、エンドユーザー別に分析しています。
- サービスの強化/革新：世界のスマートピル市場における今後の動向に関する詳細な洞察
- 市場開発：アプリケーション別、ターゲット分野別、エンドユーザー別の有利な新興市場に関する包括的情報。
- 市場の多様化：世界のスマート錠剤市場における新サービスやサービス強化、成長地域、最新動向、投資に関する詳細情報。
- 競合評価：世界のスマートピル市場における主要企業の市場シェア、成長戦略、製品提供、企業評価象限、能力を詳細に評価します。

ページTOPに戻る


目次

1 INTRODUCTION 20
1.1 STUDY OBJECTIVES 20
1.2 MARKET DEFINITION 20
1.2.1 INCLUSIONS AND EXCLUSIONS 21
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
FIGURE 1 SMART PILLS MARKET: MARKET SEGMENTATION 21
1.3.2 YEARS CONSIDERED 22
1.4 CURRENCY CONSIDERED 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 22
1.7 SUMMARY OF CHANGES 23
1.8 RECESSION IMPACT 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH APPROACH 24
FIGURE 2 RESEARCH DESIGN 24
2.1.1 SECONDARY RESEARCH 24
2.1.1.1 Key data from secondary sources 25
2.1.2 PRIMARY DATA 26
FIGURE 3 PRIMARY SOURCES 26
2.1.2.1 Key data from primary sources 27
2.1.2.2 Insights from primary experts 27
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 28
2.1.3 MARKET SIZE ESTIMATION 28
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 29
FIGURE 6 SMART PILLS MARKET: SEGMENTAL EXTRAPOLATION 30
FIGURE 7 SMART PILLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 31
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 31
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY 33
FIGURE 9 SMART PILLS MARKET: DATA TRIANGULATION METHODOLOGY 33
2.3 MARKET SHARE ANALYSIS 34
2.4 STUDY ASSUMPTIONS 34
2.5 LIMITATIONS 34
2.5.1 METHODOLOGY-RELATED LIMITATIONS 34
 
2.6 RISK ASSESSMENT 35
TABLE 1 SMART PILLS MARKET: RISK ASSESSMENT ANALYSIS 35
2.7 RECESSION IMPACT ANALYSIS 35
3 EXECUTIVE SUMMARY 36
FIGURE 10 SMART PILLS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 36
FIGURE 11 SMART PILLS MARKET, BY TARGET AREA, 2023 VS. 2028 (USD MILLION) 37
FIGURE 12 SMART PILLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 37
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF SMART PILLS MARKET 38
4 PREMIUM INSIGHTS 39
4.1 SMART PILLS MARKET OVERVIEW 39
FIGURE 14 RISING TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPES TO DRIVE MARKET 39
4.2 NORTH AMERICA: SMART PILLS MARKET, BY END USER AND COUNTRY 40
FIGURE 15 HOSPITALS ACCOUNTED FOR LARGEST MARKET SHARE IN US FOR 2022 40
4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 40
FIGURE 16 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 40
4.4 SMART PILLS MARKET: REGIONAL MIX 41
FIGURE 17 NORTH AMERICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 41
4.5 SMART PILLS MARKET: DEVELOPING VS. EMERGING MARKETS 41
FIGURE 18 EMERGING MARKETS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 41
5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.2 MARKET DYNAMICS 42
FIGURE 19 SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42
TABLE 2 SMART PILLS MARKET: IMPACT ANALYSIS 43
5.2.1 DRIVERS 43
5.2.1.1 Rising demand for noninvasive diagnostic monitoring devices 43
5.2.1.2 Technological advancements in capsule endoscopy 44
5.2.1.3 Increasing incidence of colon cancer 44
5.2.2 RESTRAINTS 45
5.2.2.1 High costs 45
5.2.2.2 Technical limitations associated with accuracy of smart pills 45
5.2.3 OPPORTUNITIES 46
5.2.3.1 Growing demand for advanced drug delivery systems 46
5.2.3.2 Rising need for rapid drug delivery development 46
5.2.4 CHALLENGES 47
5.2.4.1 Patient privacy concerns 47
 
5.3 INDUSTRY TRENDS 47
5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGY 47
5.3.2 INTEGRATION WITH WEARABLE DEVICES 48
5.4 TECHNOLOGY ANALYSIS 48
5.4.1 SELF-POWERED INGESTIBLE SMART PILL 48
5.4.2 ADAPTIVE FRAME RATE TECHNOLOGY 48
5.4.3 IMAG (INGESTIBLE MICRODEVICES FOR ANATOMIC MAPPING OF GASTROINTESTINAL TRACT) 49
TABLE 3 SENSOR AND BATTERY TYPES USED FOR CAPSULE ENDOSCOPY PRODUCTS 49
TABLE 4 SENSOR USED FOR VITAL SIGN MONITORING AND DRUG INGESTION TRACKING PRODUCTS 50
TABLE 5 SMART PILLS MARKET: DRUGS UNDER PIPELINE 51
5.5 PORTER’S FIVE FORCES ANALYSIS 52
TABLE 6 PORTER’S FIVE FORCES ANALYSIS 52
5.5.1 THREAT OF NEW ENTRANTS 52
5.5.2 THREAT OF SUBSTITUTES 53
5.5.3 BARGAINING POWER OF SUPPLIERS 53
5.5.4 BARGAINING POWER OF BUYERS 53
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 53
5.6 ECOSYSTEM ANALYSIS 54
FIGURE 20 SMART PILLS MARKET: ECOSYSTEM ANALYSIS 54
5.7 VALUE CHAIN ANALYSIS 54
FIGURE 21 SMART PILLS MARKET: VALUE CHAIN ANALYSIS 55
5.8 PATENT ANALYSIS 55
5.8.1 PATENT PUBLICATION TRENDS FOR SMART PILLS 56
FIGURE 22 PATENT PUBLICATION TRENDS (JANUARY 2012–DECEMBER 2022) 56
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 56
FIGURE 23 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILLS PATENTS (JANUARY 2012–DECEMBER 2022) 57
FIGURE 24 TOP APPLICANTS FOR SMART PILLS PATENTS (COUNTRY/REGION) (JANUARY 2012–JANUARY 2022) 57
TABLE 7 SMART PILLS MARKET: LIST OF PATENTS (2020–2023) 58
5.9 PRICING ANALYSIS 60
TABLE 8 PRICE RANGE FOR SMART PILLS (2022) 60
5.10 KEY CONFERENCES AND EVENTS 60
TABLE 9 SMART PILLS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023-2024) 60
5.11 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 10 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
5.12 REGULATORY ANALYSIS 62
5.12.1 NORTH AMERICA 62
5.12.1.1 US 62
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION 62
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 62
5.12.2 EUROPE 63
5.12.3 ASIA PACIFIC 63
5.12.3.1 Japan 63
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 63
5.12.3.2 China 64
TABLE 14 CHINA: CLASSIFICATION OF MEDICAL DEVICES 64
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 65
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 65
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION 65
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION (%) 65
5.13.2 BUYING CRITERIA 65
FIGURE 26 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION 65
TABLE 16 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION 66
6 SMART PILLS MARKET, BY TARGET AREA 67
6.1 INTRODUCTION 68
TABLE 17 SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 68
6.2 SMALL INTESTINE 68
6.2.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET 68
TABLE 18 SMART PILLS MARKET FOR SMALL INTESTINE, BY COUNTRY, 2021–2028 (USD MILLION) 69
6.3 LARGE INTESTINE 70
6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH 70
TABLE 19 SMART PILLS MARKET FOR LARGE INTESTINE, BY COUNTRY, 2021–2028 (USD MILLION) 71
6.4 ESOPHAGUS 71
6.4.1 EVALUATION AND MONITORING OF BARRETT’S ESOPHAGUS TO PROPEL MARKET 71
TABLE 20 SMART PILLS MARKET FOR ESOPHAGUS, BY COUNTRY, 2021–2028 (USD MILLION) 72
6.5 STOMACH 72
6.5.1 IMPROVED DIAGNOSTIC ACCURACY TO SUPPORT MARKET GROWTH 72
TABLE 21 SMART PILLS MARKET FOR STOMACH, BY COUNTRY, 2021–2028 (USD MILLION) 73
7 SMART PILLS MARKET, BY APPLICATION 74
7.1 INTRODUCTION 75
TABLE 22 SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 75
7.2 CAPSULE ENDOSCOPY 75
7.2.1 ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL-BOWL TUMORS TO DRIVE MARKET 75
TABLE 23 CAPSULE ENDOSCOPES OFFERED BY KEY MARKET PLAYERS 76
TABLE 24 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY COUNTRY, 2021–2028 (USD MILLION) 77
7.3 VITAL SIGN MONITORING 77
7.3.1 LAUNCH OF INNOVATIVE SENSOR TECHNOLOGIES TO PROPEL MARKET 77
TABLE 25 VITAL SIGN MONITORING SMART PILLS UNDER PIPELINE 78
TABLE 26 SMART PILLS MARKET FOR VITAL SIGN MONITORING, BY COUNTRY, 2021–2028 (USD MILLION) 78
7.4 TARGETED DRUG DELIVERY 79
7.4.1 SITE-SPECIFIC DRUG DELIVERY INTEGRATION WITH SMART PILLS TO SUPPORT MARKET GROWTH 79
TABLE 27 TARGETED DRUG DELIVERY SMART PILLS UNDER PIPELINE 80
TABLE 28 SMART PILLS MARKET FOR TARGETED DRUG DELIVERY, BY COUNTRY, 2021–2028 (USD MILLION) 80
8 SMART PILLS MARKET, BY END USER 81
8.1 INTRODUCTION 82
TABLE 29 SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 82
8.2 HOSPITALS 82
8.2.1 RISING NEED FOR TECHNOLOGICALLY ADVANCED ENDOSCOPY PROCEDURES TO DRIVE MARKET 82
TABLE 30 SMART PILLS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 83
8.3 DIAGNOSTIC CENTERS 83
8.3.1 GROWING PREFERENCE FOR NONINVASIVE DIAGNOSTICS TO PROPEL MARKET 83
TABLE 31 SMART PILLS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 84
8.4 OTHER END USERS 84
TABLE 32 SMART PILLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 85
9 SMART PILLS MARKET, BY REGION 86
9.1 INTRODUCTION 87
TABLE 33 SMART PILLS MARKET, BY REGION, 2021–2028 (USD MILLION) 87
TABLE 34 CAPSULE ENDOSCOPY MARKET, BY REGION, 2021–2028 (MILLION UNITS) 87
TABLE 35 VITAL SIGN MONITORING MARKET, BY REGION, 2021–2028 (MILLION UNITS) 88
9.2 NORTH AMERICA 88
FIGURE 27 NORTH AMERICA: SMART PILLS MARKET SNAPSHOT 89
TABLE 36 NORTH AMERICA: SMART PILLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 37 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 90
TABLE 38 NORTH AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 90
TABLE 39 NORTH AMERICA: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 90
9.2.1 US 91
9.2.1.1 Favorable reimbursements for endoscopy procedures to drive market 91
TABLE 40 US: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 92
TABLE 41 US: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 92
TABLE 42 US: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 92
9.2.2 CANADA 93
9.2.2.1 Rising incidence of IBD to drive market 93
TABLE 43 CANADA: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 93
TABLE 44 CANADA: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 93
TABLE 45 CANADA: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 94
9.2.3 NORTH AMERICA: RECESSION IMPACT 94
9.3 EUROPE 94
TABLE 46 EUROPE: SMART PILLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 47 EUROPE: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 95
TABLE 48 EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 95
TABLE 49 EUROPE: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 96
9.3.1 GERMANY 96
9.3.1.1 Rising incidence of Chron’s disease to drive market 96
TABLE 50 GERMANY: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 97
TABLE 51 GERMANY: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 97
TABLE 52 GERMANY: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 97
9.3.2 UK 98
9.3.2.1 Utilization of capsule endoscopy for bowel cancer to drive market 98
TABLE 53 UK: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 54 UK: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 99
TABLE 55 UK: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 99
9.3.3 FRANCE 99
9.3.3.1 Reimbursement coverage for small bowel capsule endoscopy to drive market 99
TABLE 56 FRANCE: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
TABLE 57 FRANCE: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 100
TABLE 58 FRANCE: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 100
9.3.4 ITALY 101
9.3.4.1 Rising adoption of technologically advanced endoscopes to support market growth 101
TABLE 59 ITALY: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 101
TABLE 60 ITALY: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 101
TABLE 61 ITALY: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 102
9.3.5 REST OF EUROPE 102
TABLE 62 REST OF EUROPE: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 102
TABLE 63 REST OF EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 103
TABLE 64 REST OF EUROPE: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.3.6 EUROPE: RECESSION IMPACT 103
9.4 ASIA PACIFIC 104
FIGURE 28 ASIA PACIFIC: SMART PILLS MARKET SNAPSHOT 104
TABLE 65 ASIA PACIFIC: SMART PILLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 66 ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 105
TABLE 67 ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 105
TABLE 68 ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
9.4.1 JAPAN 106
9.4.1.1 Rising incidence of gastric cancer to drive market 106
TABLE 69 JAPAN: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
TABLE 70 JAPAN: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 107
TABLE 71 JAPAN: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.4.2 CHINA 108
9.4.2.1 Increasing funding initiatives for development of smart pills to fuel market 108
TABLE 72 CHINA: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 108
TABLE 73 CHINA: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 109
TABLE 74 CHINA: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.4.3 INDIA 109
9.4.3.1 Rising incidence of IBD to support market growth 109
TABLE 75 INDIA: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 76 INDIA: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 110
TABLE 77 INDIA: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 110
9.4.4 REST OF ASIA PACIFIC 111
TABLE 78 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 79 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 111
TABLE 80 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 112
9.4.5 ASIA PACIFIC: RECESSION IMPACT 112
 
9.5 REST OF THE WORLD 112
TABLE 81 REST OF THE WORLD: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 113
TABLE 82 REST OF THE WORLD: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 113
TABLE 83 REST OF THE WORLD: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
10 COMPETITIVE LANDSCAPE 114
10.1 OVERVIEW 114
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 114
TABLE 84 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 115
10.2.1 REVENUE SHARE ANALYSIS 116
FIGURE 29 REVENUE SHARE ANALYSIS OF LEADING PLAYERS 116
10.2.2 MARKET SHARE ANALYSIS 117
FIGURE 30 SMART PILLS MARKET SHARE, BY KEY PLAYER (2022) 117
10.3 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS 118
10.3.1 STARS 118
10.3.2 EMERGING LEADERS 118
10.3.3 PERVASIVE PLAYERS 118
10.3.4 PARTICIPANTS 118
FIGURE 31 SMART PILLS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 119
10.4 COMPANY FOOTPRINT ANALYSIS 119
TABLE 85 SMART PILLS MARKET: COMPANY FOOTPRINT ANALYSIS 120
10.4.1 APPLICATION FOOTPRINT ANALYSIS 121
TABLE 86 SMART PILLS MARKET: APPLICATION FOOTPRINT 121
10.4.2 TARGET AREA FOOTPRINT ANALYSIS 122
TABLE 87 SMART PILLS MARKET: TARGET AREA FOOTPRINT 122
10.4.3 END USER FOOTPRINT ANALYSIS 123
TABLE 88 SMART PILLS MARKET: END USER FOOTPRINT 123
10.4.4 REGIONAL FOOTPRINT ANALYSIS 124
TABLE 89 SMART PILLS MARKET: REGIONAL FOOTPRINT 124
10.5 COMPETITIVE SCENARIO 125
10.5.1 PRODUCT LAUNCHES & APPROVALS 125
TABLE 90 SMART PILLS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–JUNE 2023) 125
10.5.2 DEALS 126
TABLE 91 SMART PILLS MARKET: DEALS (JANUARY 2020–JUNE 2023) 126
10.5.3 OTHER DEVELOPMENTS 127
TABLE 92 SMART PILLS MARKET: OTHER DEVELOPMENTS (JANUARY 2020–JUNE 2023) 127
 
11 COMPANY PROFILES 128
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1 KEY PLAYERS 128
11.1.1 OLYMPUS CORPORATION 128
TABLE 93 OLYMPUS CORPORATION: BUSINESS OVERVIEW 128
FIGURE 32 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2022) 129
11.1.2 CAPSOVISION, INC. 131
TABLE 94 CAPSOVISION, INC.: BUSINESS OVERVIEW 131
11.1.3 MEDTRONIC PLC 133
TABLE 95 MEDTRONIC PLC: BUSINESS OVERVIEW 133
FIGURE 33 MEDTRONIC PLC: COMPANY SNAPSHOT (2022) 134
11.1.4 INTROMEDIC 136
TABLE 96 INTROMEDIC: BUSINESS OVERVIEW 136
11.1.5 ANX ROBOTICA CORP. 137
TABLE 97 ANX ROBOTICA CORP.: BUSINESS OVERVIEW 137
11.1.6 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD. 139
TABLE 98 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW 139
11.1.7 CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD. 140
TABLE 99 CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD.: BUSINESS OVERVIEW 140
11.1.8 RF CO., LTD. 141
TABLE 100 RF CO., LTD.: BUSINESS OVERVIEW 141
11.1.9 ETECTRX 142
TABLE 101 ETECTRX: BUSINESS OVERVIEW 142
11.1.10 BODYCAP 143
TABLE 102 BODYCAP: BUSINESS OVERVIEW 143
11.1.11 OTSUKA AMERICA PHARMACEUTICAL, INC. 144
TABLE 103 OTSUKA AMERICA PHARMACEUTICAL, INC.: BUSINESS OVERVIEW 144
11.1.12 CHECK-CAP LTD. 145
TABLE 104 CHECK-CAP LTD.: BUSINESS OVERVIEW 145
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 147
12.1 DISCUSSION GUIDE 147
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 150
12.3 CUSTOMIZATION OPTIONS 152
12.4 RELATED REPORTS 152
12.5 AUTHOR DETAILS 153

　

ページTOPに戻る


　

Summary

The global smart pills market is projected to reach USD 1.1 billion by 2028 from USD 0.6 billion in 2023, at a CAGR of 11.8% during the forecast period. Growth in this market is majorly driven by the rise in demand for non-invasive diagnostic monitoring devices, technological advancements in capsule endoscopy and significant advancements in capsule endoscopy technology. The growing demand for advanced drug delivery systems and need for a rapid drug development process are expected to offer opportunities for market players during the forecast period. On the other hand, technological incompetence of smart pills in some conditions is expected to restrain the market growth to some extent in the coming years


“The vital sign monitoring segment is projected to grow at the highest CAGR during the forecast period.”
Based on application, the market for smart pills is divided into segments for target drug devliery, capsule endoscopy, and vital sign monitoring. The vital sign monitoring segments is projected to grow at the highest CAGR during the forecast period. This is due to the increasing need for precise and accurate measurement of inner body temperature and insufficient integration with digital health systems in conventional vital sign monitoring devices. As healthcare systems strive for interoperability and comprehensive patient records, the rising need for vital sign monitoring devices that integrate smoothly with digital health systems becomes crucial. The growing demand for streamlined integration is expected to increase the adoption of smart pills due to advanced connectivity and compatibility with digital health systems.

“The large intestine target area accounted for the second largest share of the market during the forecast period. “
Based on target area, the smart pills market is broadly segmented into, small intestine, large intestine, esophagus, and stomach. The large intestine target area accounted for the second largest share in 2022 and this is attributed to the increasing cases of colorectal cancer and need for effective screening, diagnosis, and monitoring of inflammatory bowel diseases and other gastrointestinal disorders. The increasing cases of colorectal cancer have contributed to the growing adoption of smart pills in large intestine as smart pills can reach areas of the colon that may be challenging to visualize with traditional methods.


The diagnostic centers segment accounted for the second largest share of the market in 2022
Based on end users, the smart pills market is broadly segmented into diagnostic centers, hospitals, and other end users. Diagnostic centers are the second largest end users of the smart pills market. This can be attributed to the advancements in technology, demand for non-invasive diagnostics, and improved diagnostic accuracy. The integration of smart pills in diagnostic centers has been a key factor in driving utilization by offering expanded diagnostic capabilities, enhanced patient experience, improved operational efficiency, and the ability to facilitate remote diagnostics.



Europe accounted for the second largest share of the smart pills market in 2022
In 2022, Europe accounted for the second largest share of the smart pills market. This can be attributed to factors such as growth in ageing population and increased utilization of capsule endoscopy for gastrointestinal bleeding. The endorsement of capsule endoscopy by the European Society of Gastrointestinal Endoscopy (ESGE) guidelines provides a standardized approach for healthcare professionals, enhancing the quality of care provided to patients. As a result, there is a growing demand for smart pills and related technologies, driven by the increased utilization of capsule endoscopy for gastrointestinal bleeding.


The break up of the profile of primary participants in the smart pills market:
• By Company Type: Tier 1- 60%, Tier 2- 30%, and Tier 3-10%
• By Designation: C-level Executives- 50%, Directors- 40% , and Others- 10%.
• By Region: North America- 45%, Europe- 35%, Asia Pacific- 15%, and Rest of the World- 5%.


Key players in the Smart pills market
The key players operating in the smart pills market include RF Co., Ltd (Japan), etectrx(US), Olympus Corporation (Japan), BodyCap (France), Chongqing Jinshan Science Technology (Group) Co., Ltd (China), Check-Cap Ltd. (Israel), CapsoVision,Inc. (US), ANX Robotica Corp. (US), Medtronic plc (US), IntroMedic (South Korea), Shenzen Jifu Medical Technology Co., Ltd (China) and Otsuka America Pharmaceutical, Inc. (US).
Research Coverage:
The report analyzes the smart pills market and aims at estimating the market size and future growth potential of this market based on various segments such as application, target area, and end user. The report also includes a product portfolio matrix of various smart pills products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global smart pills market. The report analyzes this market by applications, target area and end user.
• Service Enhancement/Innovation: Detailed insights on upcoming trends in the global smart pills market
• Market Development: Comprehensive information on the lucrative emerging markets by applications, target area and end user.
• Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global smart pills market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global smart pills market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 20
1.1 STUDY OBJECTIVES 20
1.2 MARKET DEFINITION 20
1.2.1 INCLUSIONS AND EXCLUSIONS 21
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
FIGURE 1 SMART PILLS MARKET: MARKET SEGMENTATION 21
1.3.2 YEARS CONSIDERED 22
1.4 CURRENCY CONSIDERED 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 22
1.7 SUMMARY OF CHANGES 23
1.8 RECESSION IMPACT 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH APPROACH 24
FIGURE 2 RESEARCH DESIGN 24
2.1.1 SECONDARY RESEARCH 24
2.1.1.1 Key data from secondary sources 25
2.1.2 PRIMARY DATA 26
FIGURE 3 PRIMARY SOURCES 26
2.1.2.1 Key data from primary sources 27
2.1.2.2 Insights from primary experts 27
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 28
2.1.3 MARKET SIZE ESTIMATION 28
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 29
FIGURE 6 SMART PILLS MARKET: SEGMENTAL EXTRAPOLATION 30
FIGURE 7 SMART PILLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 31
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 31
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY 33
FIGURE 9 SMART PILLS MARKET: DATA TRIANGULATION METHODOLOGY 33
2.3 MARKET SHARE ANALYSIS 34
2.4 STUDY ASSUMPTIONS 34
2.5 LIMITATIONS 34
2.5.1 METHODOLOGY-RELATED LIMITATIONS 34
 
2.6 RISK ASSESSMENT 35
TABLE 1 SMART PILLS MARKET: RISK ASSESSMENT ANALYSIS 35
2.7 RECESSION IMPACT ANALYSIS 35
3 EXECUTIVE SUMMARY 36
FIGURE 10 SMART PILLS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 36
FIGURE 11 SMART PILLS MARKET, BY TARGET AREA, 2023 VS. 2028 (USD MILLION) 37
FIGURE 12 SMART PILLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 37
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF SMART PILLS MARKET 38
4 PREMIUM INSIGHTS 39
4.1 SMART PILLS MARKET OVERVIEW 39
FIGURE 14 RISING TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPES TO DRIVE MARKET 39
4.2 NORTH AMERICA: SMART PILLS MARKET, BY END USER AND COUNTRY 40
FIGURE 15 HOSPITALS ACCOUNTED FOR LARGEST MARKET SHARE IN US FOR 2022 40
4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 40
FIGURE 16 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 40
4.4 SMART PILLS MARKET: REGIONAL MIX 41
FIGURE 17 NORTH AMERICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 41
4.5 SMART PILLS MARKET: DEVELOPING VS. EMERGING MARKETS 41
FIGURE 18 EMERGING MARKETS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 41
5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.2 MARKET DYNAMICS 42
FIGURE 19 SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42
TABLE 2 SMART PILLS MARKET: IMPACT ANALYSIS 43
5.2.1 DRIVERS 43
5.2.1.1 Rising demand for noninvasive diagnostic monitoring devices 43
5.2.1.2 Technological advancements in capsule endoscopy 44
5.2.1.3 Increasing incidence of colon cancer 44
5.2.2 RESTRAINTS 45
5.2.2.1 High costs 45
5.2.2.2 Technical limitations associated with accuracy of smart pills 45
5.2.3 OPPORTUNITIES 46
5.2.3.1 Growing demand for advanced drug delivery systems 46
5.2.3.2 Rising need for rapid drug delivery development 46
5.2.4 CHALLENGES 47
5.2.4.1 Patient privacy concerns 47
 
5.3 INDUSTRY TRENDS 47
5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGY 47
5.3.2 INTEGRATION WITH WEARABLE DEVICES 48
5.4 TECHNOLOGY ANALYSIS 48
5.4.1 SELF-POWERED INGESTIBLE SMART PILL 48
5.4.2 ADAPTIVE FRAME RATE TECHNOLOGY 48
5.4.3 IMAG (INGESTIBLE MICRODEVICES FOR ANATOMIC MAPPING OF GASTROINTESTINAL TRACT) 49
TABLE 3 SENSOR AND BATTERY TYPES USED FOR CAPSULE ENDOSCOPY PRODUCTS 49
TABLE 4 SENSOR USED FOR VITAL SIGN MONITORING AND DRUG INGESTION TRACKING PRODUCTS 50
TABLE 5 SMART PILLS MARKET: DRUGS UNDER PIPELINE 51
5.5 PORTER’S FIVE FORCES ANALYSIS 52
TABLE 6 PORTER’S FIVE FORCES ANALYSIS 52
5.5.1 THREAT OF NEW ENTRANTS 52
5.5.2 THREAT OF SUBSTITUTES 53
5.5.3 BARGAINING POWER OF SUPPLIERS 53
5.5.4 BARGAINING POWER OF BUYERS 53
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 53
5.6 ECOSYSTEM ANALYSIS 54
FIGURE 20 SMART PILLS MARKET: ECOSYSTEM ANALYSIS 54
5.7 VALUE CHAIN ANALYSIS 54
FIGURE 21 SMART PILLS MARKET: VALUE CHAIN ANALYSIS 55
5.8 PATENT ANALYSIS 55
5.8.1 PATENT PUBLICATION TRENDS FOR SMART PILLS 56
FIGURE 22 PATENT PUBLICATION TRENDS (JANUARY 2012–DECEMBER 2022) 56
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 56
FIGURE 23 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILLS PATENTS (JANUARY 2012–DECEMBER 2022) 57
FIGURE 24 TOP APPLICANTS FOR SMART PILLS PATENTS (COUNTRY/REGION) (JANUARY 2012–JANUARY 2022) 57
TABLE 7 SMART PILLS MARKET: LIST OF PATENTS (2020–2023) 58
5.9 PRICING ANALYSIS 60
TABLE 8 PRICE RANGE FOR SMART PILLS (2022) 60
5.10 KEY CONFERENCES AND EVENTS 60
TABLE 9 SMART PILLS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023-2024) 60
5.11 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 10 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
5.12 REGULATORY ANALYSIS 62
5.12.1 NORTH AMERICA 62
5.12.1.1 US 62
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION 62
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 62
5.12.2 EUROPE 63
5.12.3 ASIA PACIFIC 63
5.12.3.1 Japan 63
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 63
5.12.3.2 China 64
TABLE 14 CHINA: CLASSIFICATION OF MEDICAL DEVICES 64
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 65
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 65
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION 65
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION (%) 65
5.13.2 BUYING CRITERIA 65
FIGURE 26 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION 65
TABLE 16 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION 66
6 SMART PILLS MARKET, BY TARGET AREA 67
6.1 INTRODUCTION 68
TABLE 17 SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 68
6.2 SMALL INTESTINE 68
6.2.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET 68
TABLE 18 SMART PILLS MARKET FOR SMALL INTESTINE, BY COUNTRY, 2021–2028 (USD MILLION) 69
6.3 LARGE INTESTINE 70
6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH 70
TABLE 19 SMART PILLS MARKET FOR LARGE INTESTINE, BY COUNTRY, 2021–2028 (USD MILLION) 71
6.4 ESOPHAGUS 71
6.4.1 EVALUATION AND MONITORING OF BARRETT’S ESOPHAGUS TO PROPEL MARKET 71
TABLE 20 SMART PILLS MARKET FOR ESOPHAGUS, BY COUNTRY, 2021–2028 (USD MILLION) 72
6.5 STOMACH 72
6.5.1 IMPROVED DIAGNOSTIC ACCURACY TO SUPPORT MARKET GROWTH 72
TABLE 21 SMART PILLS MARKET FOR STOMACH, BY COUNTRY, 2021–2028 (USD MILLION) 73
7 SMART PILLS MARKET, BY APPLICATION 74
7.1 INTRODUCTION 75
TABLE 22 SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 75
7.2 CAPSULE ENDOSCOPY 75
7.2.1 ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL-BOWL TUMORS TO DRIVE MARKET 75
TABLE 23 CAPSULE ENDOSCOPES OFFERED BY KEY MARKET PLAYERS 76
TABLE 24 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY COUNTRY, 2021–2028 (USD MILLION) 77
7.3 VITAL SIGN MONITORING 77
7.3.1 LAUNCH OF INNOVATIVE SENSOR TECHNOLOGIES TO PROPEL MARKET 77
TABLE 25 VITAL SIGN MONITORING SMART PILLS UNDER PIPELINE 78
TABLE 26 SMART PILLS MARKET FOR VITAL SIGN MONITORING, BY COUNTRY, 2021–2028 (USD MILLION) 78
7.4 TARGETED DRUG DELIVERY 79
7.4.1 SITE-SPECIFIC DRUG DELIVERY INTEGRATION WITH SMART PILLS TO SUPPORT MARKET GROWTH 79
TABLE 27 TARGETED DRUG DELIVERY SMART PILLS UNDER PIPELINE 80
TABLE 28 SMART PILLS MARKET FOR TARGETED DRUG DELIVERY, BY COUNTRY, 2021–2028 (USD MILLION) 80
8 SMART PILLS MARKET, BY END USER 81
8.1 INTRODUCTION 82
TABLE 29 SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 82
8.2 HOSPITALS 82
8.2.1 RISING NEED FOR TECHNOLOGICALLY ADVANCED ENDOSCOPY PROCEDURES TO DRIVE MARKET 82
TABLE 30 SMART PILLS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 83
8.3 DIAGNOSTIC CENTERS 83
8.3.1 GROWING PREFERENCE FOR NONINVASIVE DIAGNOSTICS TO PROPEL MARKET 83
TABLE 31 SMART PILLS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 84
8.4 OTHER END USERS 84
TABLE 32 SMART PILLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 85
9 SMART PILLS MARKET, BY REGION 86
9.1 INTRODUCTION 87
TABLE 33 SMART PILLS MARKET, BY REGION, 2021–2028 (USD MILLION) 87
TABLE 34 CAPSULE ENDOSCOPY MARKET, BY REGION, 2021–2028 (MILLION UNITS) 87
TABLE 35 VITAL SIGN MONITORING MARKET, BY REGION, 2021–2028 (MILLION UNITS) 88
9.2 NORTH AMERICA 88
FIGURE 27 NORTH AMERICA: SMART PILLS MARKET SNAPSHOT 89
TABLE 36 NORTH AMERICA: SMART PILLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 37 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 90
TABLE 38 NORTH AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 90
TABLE 39 NORTH AMERICA: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 90
9.2.1 US 91
9.2.1.1 Favorable reimbursements for endoscopy procedures to drive market 91
TABLE 40 US: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 92
TABLE 41 US: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 92
TABLE 42 US: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 92
9.2.2 CANADA 93
9.2.2.1 Rising incidence of IBD to drive market 93
TABLE 43 CANADA: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 93
TABLE 44 CANADA: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 93
TABLE 45 CANADA: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 94
9.2.3 NORTH AMERICA: RECESSION IMPACT 94
9.3 EUROPE 94
TABLE 46 EUROPE: SMART PILLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 47 EUROPE: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 95
TABLE 48 EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 95
TABLE 49 EUROPE: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 96
9.3.1 GERMANY 96
9.3.1.1 Rising incidence of Chron’s disease to drive market 96
TABLE 50 GERMANY: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 97
TABLE 51 GERMANY: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 97
TABLE 52 GERMANY: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 97
9.3.2 UK 98
9.3.2.1 Utilization of capsule endoscopy for bowel cancer to drive market 98
TABLE 53 UK: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 54 UK: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 99
TABLE 55 UK: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 99
9.3.3 FRANCE 99
9.3.3.1 Reimbursement coverage for small bowel capsule endoscopy to drive market 99
TABLE 56 FRANCE: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
TABLE 57 FRANCE: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 100
TABLE 58 FRANCE: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 100
9.3.4 ITALY 101
9.3.4.1 Rising adoption of technologically advanced endoscopes to support market growth 101
TABLE 59 ITALY: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 101
TABLE 60 ITALY: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 101
TABLE 61 ITALY: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 102
9.3.5 REST OF EUROPE 102
TABLE 62 REST OF EUROPE: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 102
TABLE 63 REST OF EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 103
TABLE 64 REST OF EUROPE: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.3.6 EUROPE: RECESSION IMPACT 103
9.4 ASIA PACIFIC 104
FIGURE 28 ASIA PACIFIC: SMART PILLS MARKET SNAPSHOT 104
TABLE 65 ASIA PACIFIC: SMART PILLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 66 ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 105
TABLE 67 ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 105
TABLE 68 ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
9.4.1 JAPAN 106
9.4.1.1 Rising incidence of gastric cancer to drive market 106
TABLE 69 JAPAN: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
TABLE 70 JAPAN: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 107
TABLE 71 JAPAN: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.4.2 CHINA 108
9.4.2.1 Increasing funding initiatives for development of smart pills to fuel market 108
TABLE 72 CHINA: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 108
TABLE 73 CHINA: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 109
TABLE 74 CHINA: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.4.3 INDIA 109
9.4.3.1 Rising incidence of IBD to support market growth 109
TABLE 75 INDIA: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 76 INDIA: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 110
TABLE 77 INDIA: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 110
9.4.4 REST OF ASIA PACIFIC 111
TABLE 78 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 79 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 111
TABLE 80 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 112
9.4.5 ASIA PACIFIC: RECESSION IMPACT 112
 
9.5 REST OF THE WORLD 112
TABLE 81 REST OF THE WORLD: SMART PILLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 113
TABLE 82 REST OF THE WORLD: SMART PILLS MARKET, BY TARGET AREA, 2021–2028 (USD MILLION) 113
TABLE 83 REST OF THE WORLD: SMART PILLS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
10 COMPETITIVE LANDSCAPE 114
10.1 OVERVIEW 114
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 114
TABLE 84 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 115
10.2.1 REVENUE SHARE ANALYSIS 116
FIGURE 29 REVENUE SHARE ANALYSIS OF LEADING PLAYERS 116
10.2.2 MARKET SHARE ANALYSIS 117
FIGURE 30 SMART PILLS MARKET SHARE, BY KEY PLAYER (2022) 117
10.3 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS 118
10.3.1 STARS 118
10.3.2 EMERGING LEADERS 118
10.3.3 PERVASIVE PLAYERS 118
10.3.4 PARTICIPANTS 118
FIGURE 31 SMART PILLS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 119
10.4 COMPANY FOOTPRINT ANALYSIS 119
TABLE 85 SMART PILLS MARKET: COMPANY FOOTPRINT ANALYSIS 120
10.4.1 APPLICATION FOOTPRINT ANALYSIS 121
TABLE 86 SMART PILLS MARKET: APPLICATION FOOTPRINT 121
10.4.2 TARGET AREA FOOTPRINT ANALYSIS 122
TABLE 87 SMART PILLS MARKET: TARGET AREA FOOTPRINT 122
10.4.3 END USER FOOTPRINT ANALYSIS 123
TABLE 88 SMART PILLS MARKET: END USER FOOTPRINT 123
10.4.4 REGIONAL FOOTPRINT ANALYSIS 124
TABLE 89 SMART PILLS MARKET: REGIONAL FOOTPRINT 124
10.5 COMPETITIVE SCENARIO 125
10.5.1 PRODUCT LAUNCHES & APPROVALS 125
TABLE 90 SMART PILLS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–JUNE 2023) 125
10.5.2 DEALS 126
TABLE 91 SMART PILLS MARKET: DEALS (JANUARY 2020–JUNE 2023) 126
10.5.3 OTHER DEVELOPMENTS 127
TABLE 92 SMART PILLS MARKET: OTHER DEVELOPMENTS (JANUARY 2020–JUNE 2023) 127
 
11 COMPANY PROFILES 128
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1 KEY PLAYERS 128
11.1.1 OLYMPUS CORPORATION 128
TABLE 93 OLYMPUS CORPORATION: BUSINESS OVERVIEW 128
FIGURE 32 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2022) 129
11.1.2 CAPSOVISION, INC. 131
TABLE 94 CAPSOVISION, INC.: BUSINESS OVERVIEW 131
11.1.3 MEDTRONIC PLC 133
TABLE 95 MEDTRONIC PLC: BUSINESS OVERVIEW 133
FIGURE 33 MEDTRONIC PLC: COMPANY SNAPSHOT (2022) 134
11.1.4 INTROMEDIC 136
TABLE 96 INTROMEDIC: BUSINESS OVERVIEW 136
11.1.5 ANX ROBOTICA CORP. 137
TABLE 97 ANX ROBOTICA CORP.: BUSINESS OVERVIEW 137
11.1.6 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD. 139
TABLE 98 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW 139
11.1.7 CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD. 140
TABLE 99 CHONGQING JINSHAN SCIENCE & TECHNOLOGY (GROUP) CO., LTD.: BUSINESS OVERVIEW 140
11.1.8 RF CO., LTD. 141
TABLE 100 RF CO., LTD.: BUSINESS OVERVIEW 141
11.1.9 ETECTRX 142
TABLE 101 ETECTRX: BUSINESS OVERVIEW 142
11.1.10 BODYCAP 143
TABLE 102 BODYCAP: BUSINESS OVERVIEW 143
11.1.11 OTSUKA AMERICA PHARMACEUTICAL, INC. 144
TABLE 103 OTSUKA AMERICA PHARMACEUTICAL, INC.: BUSINESS OVERVIEW 144
11.1.12 CHECK-CAP LTD. 145
TABLE 104 CHECK-CAP LTD.: BUSINESS OVERVIEW 145
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 147
12.1 DISCUSSION GUIDE 147
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 150
12.3 CUSTOMIZATION OPTIONS 152
12.4 RELATED REPORTS 152
12.5 AUTHOR DETAILS 153

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（diagnostic centers）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/09/20　10:26

143.76 円

160.81 円

193.57 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.